Opportunity Information: Apply for RFA CA 13 015
Apply for RFA CA 13 015
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Cancer Detection, Diagnostic and Treatment Technologies for Global Health (UH2/UH3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Oct 30, 2013 and posted on Oct 30, 2013.
- Applicants must submit their applications by Jan 6, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses For profit organizations other than small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cancer Detection, Diagnostic and Treatment Technologies for Global Health (UH2/UH3) funding opportunity (RFA-CA-13-015) was a National Institutes of Health (NIH) initiative designed to push cancer technology development in a very practical direction: tools that can actually work in low- and middle-income countries (LMICs). The core aim was to support projects that take existing or emerging cancer technologies and adapt, apply, and validate them into a new generation of low-cost, user-friendly devices or assays. The expectation was not just incremental tweaks, but meaningful engineering and clinical translation so that the resulting products would be clinically comparable to technologies already used for cancer imaging, in vitro detection and diagnosis, or cancer treatment, while being far more feasible in resource-constrained settings.
A key emphasis of the FOA was suitability for LMIC realities. That generally means technologies that can tolerate limited infrastructure, intermittent electricity, constrained budgets, reduced access to specialized maintenance and consumables, and shortages of highly trained personnel. In practice, the initiative was focused on making tools simpler to use, cheaper to deploy, and more robust, without sacrificing clinical credibility. Projects were expected to move beyond conceptual feasibility and into adaptation and validation, indicating that applicants needed a pathway to demonstrate performance and comparability rather than stopping at early prototyping.
The award mechanism was a cooperative agreement using the UH2/UH3 structure. This kind of structure is commonly used when an agency anticipates substantial programmatic involvement and wants to support a milestone-driven progression from an earlier, development-focused phase (UH2) into a later, validation and translation-focused phase (UH3). While the source text does not spell out the specific milestones, the presence of the phased cooperative agreement mechanism signals that NIH intended to actively manage progress and that projects would likely need to meet defined benchmarks to advance between phases.
From a funding standpoint, the FOA listed an estimated total funding amount of $3,000,000, with no cost sharing or matching requirement. The opportunity was categorized as discretionary funding and tied to NIH activity areas under CFDA 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research), reflecting the broad scope across detection, diagnosis, and treatment technologies.
Eligibility was fairly broad across US-based organizations. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), small businesses, for-profit organizations other than small businesses, and state governments. The announcement also explicitly included various designated institution types such as Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with eligible federal agencies and US territories or possessions. At the same time, it restricted foreign participation in an important way: non-US entities (foreign institutions) were not eligible to apply, and non-US components of US organizations were also not eligible. However, foreign components, as defined by the NIH Grants Policy Statement, were allowed, which generally creates room for well-structured international collaborations and on-the-ground LMIC validation work while keeping the applicant organization US-based.
Timing details show this was a time-limited call. The FOA was posted on October 30, 2013, with an original and current closing date of January 6, 2014, and an archive date of February 6, 2014. That short submission window aligns with a targeted initiative meant to stimulate a specific pipeline of proposals rather than an open-ended program.
Overall, the opportunity was about translating cancer technologies into forms that fit LMIC clinical environments: affordable, durable, and simple to deploy, yet still clinically credible when compared against established imaging, diagnostic, and treatment standards. The cooperative agreement, phased UH2/UH3 design, and the explicit call for adaptation and validation all point to NIH prioritizing projects that could realistically progress toward usable tools rather than remaining purely academic or exploratory.
Source link provided in the notice: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-13-015.html
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is the Cancer Detection, Diagnostic and Treatment Technologies for Global Health (UH2/UH3) funding opportunity announcement (FOA), identified as RFA-CA-13-015. It was an NIH initiative focused on developing cancer-related technologies that are practical and usable in low- and middle-income countries (LMICs).
What was the main goal of RFA-CA-13-015?
The main goal was to support projects that take existing or emerging cancer technologies and adapt, apply, and validate them into a new generation of low-cost, user-friendly devices or assays that can work in LMIC settings.
What kinds of cancer technologies were in scope?
The FOA covered technologies related to cancer imaging, in vitro detection and diagnosis, and cancer treatment. The scope was broad across detection, diagnosis, and treatment technologies, as reflected by the associated CFDA program areas.
Was the focus on creating completely new inventions or improving existing tools?
The emphasis was on meaningful engineering and clinical translation rather than minor updates. Projects were expected to adapt and validate technologies so the end product would be feasible in resource-constrained settings while maintaining clinical credibility comparable to established tools.
What does "clinically comparable" mean in the context of this FOA?
Based on the description, projects were expected to produce tools that could be considered clinically comparable to technologies already used for cancer imaging, in vitro detection/diagnosis, or treatment, but in forms that are far more feasible for LMIC environments (for example, lower cost, easier to use, and more robust).
Why were LMIC settings specifically emphasized?
The initiative was designed around LMIC realities, where clinical environments may have limited infrastructure, intermittent electricity, constrained budgets, reduced access to specialized maintenance and consumables, and shortages of highly trained personnel.
What characteristics were expected of LMIC-suitable technologies?
Technologies were expected to be affordable, durable, and simpler to use. They should tolerate limited infrastructure and other resource constraints without sacrificing clinical credibility.
Were applicants expected to go beyond early prototypes?
Yes. The FOA emphasized moving beyond conceptual feasibility into adaptation and validation, meaning projects needed a path to demonstrate performance and comparability rather than stopping at early prototyping.
What award mechanism was used?
The award mechanism was a cooperative agreement using the UH2/UH3 phased structure.
What does the UH2/UH3 structure imply for how projects progress?
The UH2/UH3 structure signals a milestone-driven progression from an earlier development-focused phase (UH2) into a later validation and translation-focused phase (UH3). It also suggests NIH expected substantial programmatic involvement and would actively manage progress, with advancement likely depending on meeting defined benchmarks.
Did the FOA list specific milestones?
The provided description does not include specific milestones. However, it notes that the phased cooperative agreement mechanism implies that defined benchmarks were likely involved for progression between UH2 and UH3.
How much total funding was estimated for this opportunity?
The FOA listed an estimated total funding amount of $3,000,000.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
What type of funding category was this?
The opportunity was categorized as discretionary funding.
Which CFDA program areas were associated with this FOA?
The FOA was tied to NIH activity areas under CFDA 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research).
Who was eligible to apply?
Eligibility was broad for US-based organizations. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain nonprofits without 501(c)(3) status), small businesses, for-profit organizations other than small businesses, and state governments.
Were minority-serving institutions explicitly included as eligible applicants?
Yes. The announcement explicitly included designated institution types such as HBCUs, TCCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs (among others listed in the notice summary).
Could federal entities apply?
Yes. The eligibility list included eligible federal agencies.
Were US territories or possessions included in eligibility?
Yes. The eligibility language included US territories or possessions.
Could foreign institutions apply directly?
No. Non-US entities (foreign institutions) were not eligible to apply under this FOA.
Could a US organization apply if part of the work was to be conducted at a non-US component of that US organization?
No. The FOA stated that non-US components of US organizations were not eligible.
Were any forms of international collaboration allowed?
Yes. Foreign components (as defined by the NIH Grants Policy Statement) were allowed. This generally creates room for structured international collaborations and LMIC on-the-ground validation work while keeping the applicant organization US-based.
When was the FOA posted?
The FOA was posted on October 30, 2013.
What was the application closing date?
The original and current closing date was January 6, 2014.
When was the FOA archived?
The archive date was February 6, 2014.
Was this an ongoing program or a time-limited call?
It was a time-limited call, with a short submission window and an archive date shortly after the closing date.
Where can the full FOA be found?
The notice provided this source link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-13-015.html
Browse more opportunities from the same category: Education Health
Next opportunity: Fiscal Year (FY) 2013 Assistance to Firefighters Grants (AFG)
Previous opportunity: National Non Profit Organization Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 13 015
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 13 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Population based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data (U54) Apply for RFA CA 14 001 Funding Number: RFA CA 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $650,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 13 386 Funding Number: PAR 13 386 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Low Cost, Pragmatic, Patient Centered Randomized Controlled Intervention Trials (UH2/UH3) Apply for RFA HL 14 019 Funding Number: RFA HL 14 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42) Apply for PA 13 388 Funding Number: PA 13 388 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44) Apply for PA 13 387 Funding Number: PA 13 387 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program(NCORP) Community Sites (UM1) Apply for RFA CA 13 013 Funding Number: RFA CA 13 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Research Bases (UM1) Apply for RFA CA 13 012 Funding Number: RFA CA 13 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UM1) Apply for RFA CA 13 014 Funding Number: RFA CA 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA MH 14 214 Funding Number: RFA MH 14 214 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Indo US Collaborative Program on Affordable Medical Devices (R03) Apply for PAR 13 390 Funding Number: PAR 13 390 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| NCI Small Grants Program for Cancer Research (NCI Omnibus R03) Apply for PAR 14 007 Funding Number: PAR 14 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Identification of Gene Variants for Addiction Related Traits by Next Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3) Apply for PAR 14 010 Funding Number: PAR 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| The Palliative Care Research Cooperative (PCRC) Enhancing Sustainability and Building the Science of Palliative Care (R01) Apply for RFA NR 14 003 Funding Number: RFA NR 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Revision Applications for Research on Genomic Underpinnings of Response to Rehabilitation Interventions (R01) Apply for PAR 14 012 Funding Number: PAR 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Genomic Underpinnings of Response to Rehabilitation Interventions (R01) Apply for PAR 14 011 Funding Number: PAR 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Functional Genetics, Epigenetics, and Non coding RNAs in Substance Abuse (R01) Apply for PA 14 014 Funding Number: PA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Genetics, Epigenetics, and Non coding RNAs in Substance Abuse (R21) Apply for PA 14 013 Funding Number: PA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Public Health Impact of the Changing Policy/Legal Environment for Marijuana (R01) Apply for PAS 14 020 Funding Number: PAS 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Discovering Novel Targets The Molecular Genetics of Drug Addiction and Related Co Morbidities (R01) Apply for PA 14 025 Funding Number: PA 14 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic Mechanisms of Brain Development for Substance Use and Dependence (R01) Apply for PA 14 026 Funding Number: PA 14 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 13 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.